Resolor prucalopride regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending Resolor prucalopride to treat constipation in women who have tried at least two different types of laxative and lifestyle changes for at least 6 months, but have not had relief from constipation. NICE is accepting comments on the draft guidance until Aug. 24. Movetis has rights to the serotonin (5-HT4) receptor agonist in Europe from Johnson & Johnson, which spun out Movetis in 2006. ...